Bio Green Med Solution, Inc. — Director's Dealing 2023

Jul 3, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cyclacel Pharmaceuticals, Inc. (CYCC)
CIK: 0001130166
Period of Report: 2023-06-30

Reporting Person: Rombotis Spiro George (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-30	Stock Option (right to buy)	$0.5891	A	110000	Acquired	2033-06-30	Common Stock (110000)	Direct

Footnotes

F1: The reporting person received an award of 110,000 options on June 30, 2023, which shall vest in full on June 30, 2026, provided, however, that if certain clinical milestones are achieved then such options shall vest in full earlier in connection with such achievement.